The Drug Price Competition and Patent Term Restoration Act of 1984, universally called the Hatch-Waxman Act, set the rules under which generic drugs come to market in the United States. It also created the Paragraph IV mechanism — the legal challenge that determines when a generic can launch.
For brand-drug investors, the Hatch-Waxman framework defines the patent cliff — the year a billion-dollar drug suddenly faces generic competition. For specialty / generic investors, it defines the first-to-file exclusivity opportunity.
The structure
To bring a generic to market, a manufacturer files an Abbreviated New Drug Application (ANDA). The ANDA references the brand drug's existing safety and efficacy data instead of replicating it. As part of the ANDA, the generic must make a certification about each patent listed in the FDA's Orange Book:
- Paragraph I — no patent is listed
- Paragraph II — listed patent has expired
- Paragraph III — generic will wait until patent expires
- Paragraph IV — listed patent is invalid, unenforceable, or not infringed
A Paragraph IV certification is the legal challenge. It triggers:
- 30-month stay — once the brand sponsor sues for infringement (within 45 days), the FDA cannot approve the ANDA for 30 months
- 180-day generic exclusivity — the first successful Paragraph IV challenger gets 180 days of generic monopoly
- At-risk launch — the generic may launch before the lawsuit resolves; if they lose, treble damages
Investment implications
For brand investors:
- A Paragraph IV filing on a key drug = potential cliff timing window
- Loss of the patent suit = generics launch within months, brand revenue typically drops 70–90% in the first year
- Win the suit = additional years of exclusivity, can be material to valuation
- Watch Orange Book delistings — those often signal settlement language
For generic investors:
- First-to-file Paragraph IV = lottery ticket; 180-day exclusivity on a $1B+ drug = $200–500M revenue
- The Orange Book + FDA's Paragraph IV list (public) reveals all active challenges
- Settlements are common and often pre-launch
Practical signals
- Brand 10-K disclosures of patent litigation (Item 3 of 10-K)
- Orange Book changes (FDA publishes monthly)
- PACER filings — the litigation itself is public via federal courts
- FDA's Paragraph IV ANDA Submissions list — published quarterly
The 30-month stay timing matters
When the brand sponsor sues, the 30-month stay starts running. The trial usually concludes during this period. If the patent is upheld, the generic must wait until expiry. If invalidated, the generic can launch immediately.
For brand investors, the date the 30-month stay expires is the catalyst — that's when generics can theoretically enter even if litigation is unresolved.
Yeji coverage
Hatch-Waxman litigation tracking is on the roadmap (Year 2). For now we surface 10-K disclosures of material patent litigation as part of the filings stream.